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ABSTRACT
Objectives: Hypoglycemia is a common side effect of antid-
iabetic therapy. In addition to reducing well-being, hypogly-
cemic events may lead to substantial costs of medical care
and lost productivity. The cost of hypoglycemia is, however,
not well identiﬁed, particularly in patients with Type 2 dia-
betes. The purpose of this study was to assess the cost of
hypoglycemia in Type 2 diabetes in Sweden.
Methods: A cost-of-illness approach, based on an incidence
methodology, was used to estimate the cost of hypoglycemia
in patients with Type 2 diabetes. A hypoglycemic event was
deﬁned as an episode with symptoms of low blood glucose
levels during which the patient required assistance from
another person. The events were divided into mild, moder-
ate, and severe, and the incidence and costs of the different
events were estimated based on data in the literature.
Results: Assuming that there are 300,000 patients with Type
2 diabetes in Sweden, it was estimated that 26,942 hypogly-
cemic events would occur annually in these patients, corre-
sponding to a rate of 0.09 events per patient-year. The total
cost of hypoglycemia was, in base case, estimated at about
€4,250,000 (€14 per patient with Type 2 diabetes) per year.
Moderate hypoglycemia contributed the largest proportion
of these costs.
Conclusions: The results indicate that hypoglycemic events
lead to substantial costs, but data are scarce and more studies
are needed to better understand the cost and consequences of
hypoglycemia.
Keywords: cost of illness, hypoglycemia, Sweden, Type 2 dia-
betes mellitus.
Introduction
In Sweden the prevalence of diabetes mellitus has been
estimated to be about 3%, with Type 2 diabetes
accounting for 85% to 90% of all diabetes cases [1].
The prevalence of Type 2 diabetes is increasing, mostly
resulting from the aging population, but also resulting
from changes in lifestyle factors (diet, exercise, smok-
ing, etc.). By 2030, the World Health Organization
predicts that diabetes will affect more than 370 million
people worldwide [2]. Because diabetes is a major
cause of morbidity and premature mortality, it has sig-
niﬁcant socioeconomic implications in both industrial-
ized and developing nations, and the largest share of
the costs is attributable to late complications of the dis-
ease (micro- and macroangiopathy) [1,3,4].
It is already well established that tight glycemic
control reduces the development of diabetic complica-
tions [5,6]. Nevertheless, glycemic control is often for-
feited to avoid treatment-related hypoglycemia, a
common and feared side effect of insulin treatment
[7]. The symptoms of hypoglycemia vary from very
mild, for example, dizziness or headache, to severe
symptoms requiring hospitalization. The prevalence of
hypoglycemia varies depending on therapy options; in
general, insulin therapy has been associated with the
greatest incidence of hypoglycemia [8]. A large pro-
portion of patients with Type 2 diabetes are treated
with insulin [1], but hypoglycemia is less common in
Type 2 versus Type 1 diabetes. Nevertheless, it is a
cause for concern, and tends to be under-recognized
[9]. Moreover, as physicians continue to move toward
tighter glycemic controls in these patients, the inci-
dence of hypoglycemia in Type 2 patients may
increase in the future.
The cost of hypoglycemia is a complex issue as
hypoglycemia affects the diabetic patient in multiple
ways, and also because of the varying deﬁnitions of
hypoglycemic events. Costs are incurred when health-
care resources are consumed to treat hypoglycemia
(direct medical costs), and also because of loss in pro-
duction when patients are absent from work (indirect
costs). The direct medical costs in association with a
hypoglycemic event depend on the severity of the
event. Severe hypoglycemia may result in hospitaliza-
tion, the moderate forms may need emergency care
and consultation by a physician, and a mild hypogly-
cemic event may only require a glucagon injection or
other assistance at the place of the event.
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Although the impact of hypoglycemia on quality of
life (QoL) is unclear, patients experiencing several epi-
sodes of hypoglycemia have reported lower QoL [10].
Whether patients with low QoL experience many
hypoglycemic events, or whether many hypoglycemic
events lead to low QoL is, however, not known.
Apart from the distressing acute symptoms,
hypoglycemia may also have a negative impact on the
health of a patient with diabetes in the long term [11].
Another important aspect is the constant fear of devel-
oping hypoglycemia that some patients experience
[12].
Few empirical studies have assessed the cost of
hypoglycemia. Leese et al. estimated the cost of severe
hypoglycemia to be about £380 per event [13] and a
French study estimated the total hospital cost of a stay
for hypoglycemia to FF14,000 (US$2100) [14]. A Ger-
man study estimated the cost of severe hypoglycemia
to US$44,338/100,000 inhabitants [15]. There is little
data on the speciﬁc costs of hypoglycemia in Type 2
diabetes. The purpose of this study was therefore to
assess the cost of hypoglycemia in Type 2 diabetes in
Sweden.
Research Design and Methods
Method for Analysis of the Cost of Hypoglycemia
Cost-of-illness methodology was used to estimate the
cost of hypoglycemia in patients with Type 2 diabetes
in Sweden. The study design was incidence-based,
considering all new events of hypoglycemia during a
given year [16,17]. A bottom-up approach was used,
with the costs of different hypoglycemic events being
calculated and extrapolated to a national level, based
on the estimated incidence rates of hypoglycemia. The
calculation model is illustrated schematically in
Figure 1.
Deﬁnition of Hypoglycemic Events
A hypoglycemic event was deﬁned as an episode of
hypoglycemia during which the patient required assist-
ance from another person to resolve the situation
(Table 1). A mild event required no medical attention
and assistance from family or friends only. A moderate
event required the help of medical personnel, typically
a physician visit, but did not require admission to a
hospital. A severe event was deﬁned as a hypoglycemic
episode requiring inpatient care. This deﬁnition of
severe hypoglycemia differs from another deﬁnition
often found in the literature, namely an event during
which the patient requires assistance. This classic def-
inition is not associated with resource use; therefore,
the alternative deﬁnition was applied for the purposes
of this analysis.
The deﬁnitions and reporting of rates of hypoglyc-
emic events varies between studies in the literature.
Many studies report the risk of having at least one
event during a speciﬁed time period, whereas others
report total number of events per patient per unit of
time. As our summary estimates include studies that
report the risk of having at least one event, there may
be a slight underestimation of the total number of
events as these patients may have experienced multiple
events during the time period.
Cost Calculations
Direct as well as indirect costs of hypoglycemia were
considered. Direct costs included costs for the medical
treatment of hypoglycemia, and indirect costs included
productivity lost because of hypoglycemic events.
When calculating the cost of lost productivity three
basic assumptions were made: 1) a person experienc-
ing a hypoglycemic event would not return to work
that day; 2) if the event occurred at night, half a day of
productivity would be lost; and 3) an event occurring
after work but before sleep would result in no loss of
productivity. Probabilities of a hypoglycemic event
occurring at different times of the day were based on
published data in patients with Type 1 diabetes [18].
There are no equivalent data available for patients
with Type 2 diabetes; the analysis assumes that the
diurnal patterns of hypoglycemia is comparable in
Type 2 diabetes.
Figure 1 Model description.
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Table 1 Deﬁnition of hypoglycemic events
Hypoglycemia Deﬁnition
Mild Patient experiences symptoms of hypoglycemia and 
requires assistance from a second person (a relative 
or friend, etc.) to resolve the situation. No medical 
attention is needed
Moderate Patient seeks medical attention for hypoglycemia but is 
not admitted to hospital overnight
Severe Patient is admitted to hospital because of hypoglycemia
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Intangible costs of hypoglycemia or effects on the
QoL of patients were not included in the analysis
because of a lack of published data.
All  costs  are  estimated  in  a  Swedish  context  and
are presented in € 2005 value (1 € = 9.1 SEK [Swedish
kronor]).
Results
Incidence of Hypoglycemia
The incidence of hypoglycemia was based on ﬁndings
from several published studies, which are summarized
in Table 2.
The incidence of hypoglycemia in patients using
metformin treatment has been found to be very low
and we therefore assumed for the purposes of this
analysis that these patients have no hypoglycemic
events. We assumed hypoglycemia incidence rates of
1.8% for patients using oral antidiabetic agents
(OADs) other than metformin and 6.9% for patients
using insulin. These assumed incidence rates were
based on the results of the studies in Table 2. Never-
theless, these rates do not include very mild events that
can be resolved without medical attention. To calcu-
late the relative incidence of mild versus moderate and
severe events, data from O’Brien et al. were used [19].
In this United States analysis the proportion of mild,
moderate, and severe hypoglycemic events, according
to the deﬁnitions used in the present study, was 71%,
28%, and 1%, respectively.
Swedish prescription statistics show that about
32% of the prescribed doses of OADs were for met-
formin. We therefore assumed that 68% of the patients
on OADs will use drugs other than metformin, which
means that we assume a hypoglycemia incidence rate
among all OAD users of about 1.2%. Thus, the aver-
age incidence rate of all hypoglycemic events was esti-
mated to  be  0.042  and  0.24  events  per  patient-year
for patients using OADs and insulin treatments,
respectively.
Cost of Hypoglycemic Events
Mild hypoglycemia. It was assumed that patients who
required assistance by another person but did not need
medical attention would receive a glucagon injection at
a price of €26.0 [20]. This was based on a previously
estimated direct cost of a mild hypoglycemic event in
patients with Type 1 diabetes [21]. Nordfeldt et al.
[21] calculated the costs of hypoglycemic events in
adolescents and children with Type 1 diabetes.
Resource use was estimated from prospectively col-
lected data of self-reported severe hypoglycemia in 129
patients below 19 years of age. Among other resource
items, they included time that the parent had to spend
away from work (i.e., lost productivity) to care for the
child. In the case of adults with diabetes the produc-
tion loss is twofold: that of the person experiencing the
hypoglycemic event and that of the person providing
assistance. Nordfeldt et al. [21] did not use the same
distinction of severe events, but for the events that did
not involve unconsciousness, 21 full days of produc-
tion were lost to care for 95 events, equating to
0.22 days (1.76 h) lost per event. It is likely that caring
for an adult patient would consume less time than car-
ing for a child, however, in the case of an adult, both
persons are likely to be part of the work force. With
these two conﬂicting inﬂuences, the estimate should
give equivalent actual time lost. Based on these data,
the indirect cost of a mild hypoglycemic event was esti-
mated to be €37.0, based on an average hourly wage
rate, including beneﬁts, and taxes (the labor cost for
the employer), of €21.0 [22].
Moderate  hypoglycemia. Costs were attributed to
four possible outcomes for moderate hypoglycemia:
visit to a general practitioner (GP); emergency room
visit; home visit from the GP; or use of an ambulance;
a possibility with emergency room visits. Unit costs for
these, based on published data, were estimated at
€129.7 for a GP visit [1], €343.4 for an emergency
Table 2 Data used to derived incidence of hypoglycemia
Study Data available Incidence of hypoglycemia
Miller et al. [8] Incidence of hypoglycemia in patients with Type 2 diabetes by 
treatment type
Overall: 24.5% of patients over 8 months Insulin: 30% of
patients over 8 months 
Oral: 16% of patients over 8 months
Diet alone: 12% of patients over 8 months
Leese et al. [13] Incidence of severe hypoglycemia requiring assistance of medical 
personnel
Insulin: 11.8 events/100 patients/year Sulfonylurea: 0.9 
events/100 patients/year
In patients with Type 2 diabetes by treatment type Metformin: 0.05 events/100 patients/year
van Staa et al. [25] Incidence of recorded hypoglycemic events Sulfonylurea: 1.8% of patients per year
Holstein et al. [15] Incidence of severe hypoglycemia in patients with Type 2 diabetes Overall: 0.4% of patients per year
UKPDS [5] Incidence of severe hypoglycemia in patients with Type 2 diabetes 
by treatment type
Insulin: 2.1–11.7% of patients per year
Oral: 0–2.5% of patients per year
O’Brien et al. [19] Proportion of mild, moderate, and severe hypoglycemic events Mild: 71% of patients
Moderate: 28% of patients
Severe: 1% of patients
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room visit [21], €233.3 for a GP home visit [1] and
€185.3 for an ambulance [21]. Based on the resource
utilization described in the diabetes control and com-
plications trial (DCCT) [23], assuming that all events
leading to hospitalization required the use of an ambu-
lance, 9% of cases of moderate hypoglycemia will
result in GP visits, 45% in emergency room visits, 45%
in GP home visits and 33% the use of an ambulance.
The weighted average costs and probabilities of each
of  the  ﬁrst  three  events  were  summed,  and  the  costs
of ambulance transportation added separately. This
resulted in a total direct medical cost of €334.7 for
each event of moderate hypoglycemia.
Indirect costs of moderate hypoglycemia were
based on the assumptions that 16% of hypoglycemic
events will occur between 08:00 and 13:00, 9% will
occur between 13:00 and 18:00, 35% will occur
between 18:00 and 00:00 and 40% will occur between
00:00 and 08:00 [18]. Hypoglycemia occurring at
these times would result in the loss of 0.75, 0.25, 0,
and 0.5 days of productivity, respectively. This equates
to an average of 0.35 days lost per event. According to
National Statistics, 77% of the population aged 18 to
65 years in Sweden are employed [22]. Applying this
percentage to the current study, this would mean that
0.27 days (or 2.16 working hours) would be lost for
each moderate event, translating to an indirect cost of
€45.3.
Severe hypoglycemia. A study in France reported that
10,800 out of 40,000 events of severe hypoglycemia
led to hospitalization [14]. The average length of stay
in hospital was 6.6 days, at a cost of FF14,000 (at
1992 prices). This is similar to the average length of
stay for patients hospitalized because of diabetes under
the diagnosis-related groups (DRG) in Sweden, equat-
ing to an average cost of €2806.8 for each severe event
leading to hospitalization [14]. In addition, the indirect
cost of lost productivity from spending 6.6 days
(52.8 h) in hospital would be €1110.6.
The total costs, both direct and indirect, of the dif-
ferent types of hypoglycemic events in Sweden are
summarized in Table 3.
Total Costs of Hypoglycemia
Indirect costs will be incurred only in patients of a
working age. Given that these costs form a relatively
substantial portion of the total costs of hypoglycemia,
we made the following assumption to estimate the
share of patients with Type 2 diabetes who are of
working age. According to Swedish prescription statis-
tics during the year 2000, approximately 37% of pre-
scribed OADs were for patients aged less than
65 years; therefore, we estimated that 37% of patients
with Type 2 diabetes are of working age.
Assuming that there are 300,000 patients with Type
2 diabetes in Sweden [1,24], we would expect 26,942
hypoglycemic events to occur annually in these
patients, corresponding to an average rate of 0.09
events per patient-year (Table 4).
From this base case assumption, the total cost of
hypoglycemia in patients with Type 2 diabetes in Swe-
Table 3 Summary of the costs of hypoglycemic events (€ per
event)
Direct costs Indirect costs Total costs
Mild hypoglycemia 26.0 37.0 63.0
Moderate hypoglycemia 334.7 45.3 380.0
Severe hypoglycemia 2806.8 1110.6 3917.4
Table 4 Expected number of hypoglycemic events per year
Insulin users
aged 
≤65 years
Insulin users
aged 
>65 years
Oral treatment
users aged 
≤65 years
Oral treatment
users aged 
>65 years
All Type 2 
patients
Incidence (events per patient) 0.24 0.24 0.042 0.042 0.09
No. of patients in Sweden 33,300 56,700 47,064 80,136 300,000
No. of mild events 5,674 9,662 1,403 2,390 19,129
No. of moderate events 2,238 3,810 553 942 7,544
No. of severe events 80 136 20 34 269
Table 5 Expected yearly cost of hypoglycemic events
Cost
Insulin users
aged 
≤65 years
Insulin users
aged 
>65 years
Oral treatment
users aged 
≤65 years
Oral treatment
users aged 
>65 years
All Type 2
patients
Mild events (M€) 0.35 0.26 0.09 0.03 0.73
Moderate events (M€) 0.85 1.28 0.21 0.31 2.65
Severe events (M€) 0.31 0.39 0.08 0.10 0.87
Total (M€) 1.52 1.91 0.38 0.45 4.25
Per Type 2 patient (€) 45.7 33.7 8.0 5.6 14.1
M€, million €.
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den was estimated to be approximately €4,250,000
(€14.1 per patient with Type 2 diabetes). Moderate
hypoglycemia contributed the largest proportion of
these costs (Table 5).
Given that the incidence estimates used to derive
these costs are uncertain, the impact of differing event
rates and proportion of mild, moderate, and severe
events on cost estimates were evaluated (Table 6).
Discussion
Hypoglycemia is common in patients with diabetes,
although the incidence of different degrees of hypogly-
cemia remains uncertain. This study estimated that
patients with Type 2 diabetes would on average expe-
rience about 0.09 hypoglycemic events per year, which
translates into 27,000 events annually in Sweden at a
total cost of €4 million, or €14 per patient with Type 2
diabetes. Moderate hypoglycemic events were the larg-
est contribution to the total cost. The risk of hypogly-
cemic events may be slightly underestimated, because
it is partly based on studies reporting the risk of
patients experiencing at least one event rather than the
total number of events.
The calculated cost did not include the intangible
cost of hypoglycemic events or of the fear of develop-
ing hypoglycemia. Mortality associated with hypo-
glycemia was also excluded; a mortality rate of
approximately 0.04% has been reported for mild and
moderate hypoglycemic events, and the mortality after
a severe event (hospitalization) has been estimated at
1.9% [14,21]. Another possibly important effect of a
reduction in the risk of hypoglycemia is an improve-
ment in glycemic control, which may lead to a reduced
risk of macrovascular complications. The conse-
quences of this in terms of costs and well-being are,
however, difﬁcult to assess, but could possible be even
more  important  than  the  short-term  consequences
of hypoglycemia. Given that these factors were not
included, the costs associated with hypoglycemia in
patients with Type 2 diabetes may be even higher than
those reported here.
In conclusion, the results of this analysis show
that hypoglycemic events in patients with Type 2
diabetes are associated with substantial costs. Data
regarding this treatment-related side effect are, how-
ever, scarce and more studies are needed to better
understand the cost and consequences of hypoglyc-
emia. Incidence and resource use for hypoglycemia,
in particular for mild hypoglycemia are therefore
important areas for further research. The effects of
hypoglycemia on QoL and the willingness to pay for
avoiding hypoglycemic events are also interesting
subjects for future study.
Source of ﬁnancial support: The analysis was supported by
an unrestricted grant from Aventis Pharma.
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